Liposomal Gel Of Ciprofloxacin For Better Treatment Of Periodontal Disease

Periodontal disease, a prevalent oral health issue, is characterized by inflammation and infection of the supporting structures of the teeth, often leading to tooth loss if untreated. Traditional treatments, including systemic antibiotics, may not achieve adequate local concentrations at the site of infection, leading to suboptimal therapeutic outcomes. This study explores the development of a liposomal gel formulation of ciprofloxacin, aimed at enhancing localized delivery and improving treatment efficacy for periodontal disease. Ciprofloxacin, a broad-spectrum fluoroquinolone antibiotic, was encapsulated in liposomes to enhance its stability, bioavailability, and penetration into periodontal tissues. The liposomal gel was characterized for its physicochemical properties, including particle size, zeta potential, drug loading capacity, and release kinetics. In vitro studies demonstrated controlled release profiles, indicating sustained drug availability over time. Viability assays and in vivo evaluations were conducted to assess the safety and efficacy of the formulation. The results indicated significant antibacterial activity against periodontal pathogens, with improved patient compliance due to the gel's ease of application. Stability studies confirmed the formulation's robustness under various storage conditions. This innovative liposomal gel of ciprofloxacin presents a promising alternative for the treatment of periodontal disease, potentially leading to enhanced therapeutic outcomes and improved patient adherence to treatment regimens. Further clinical trials are warranted to validate these findings and establish the formulation's effectiveness in a clinical setting.